Stockscreener 앱 받기
20.83
1.02%
0.21
시간 외 거래:
20.82
-0.010
-0.05%
전일 마감가:
$20.62
열려 있는:
$20.47
하루 거래량:
1.15M
Relative Volume:
0.57
시가총액:
$2.36B
수익:
$6.94M
순이익/손실:
$-212.39M
주가수익비율:
-8.5791
EPS:
-2.428
순현금흐름:
$-200.60M
1주 성능:
-0.76%
1개월 성능:
-5.92%
6개월 성능:
+121.83%
1년 성능:
+143.06%
1일 변동 폭
$20.02
$20.98
1주일 범위
$19.81
$21.40
52주 변동 폭
$5.1501
$27.65
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.83 | 2.33B | 6.94M | -212.39M | -200.60M | -2.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Behavioral Patterns of IMNM and Institutional Flows - Stock Traders Daily
HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN
This Sezzle analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Stephens & Co. Maintains Immunome (IMNM) Overweight Recommendation - MSN
Immunome Inc Stock (ISIN: US45254C1062) Eyes Upside as Lock-Up Expires Today Amid Short-Term Buy Sig - AD HOC NEWS
Forecast Cut: What is the long term forecast for Immunome Inc stockBond Market & Fast Gain Stock Trading Tips - baoquankhu1.vn
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - AOL.com
Pivotal bioVenture Partners Investment Advisor LLC Invests $5.88 Million in Immunome, Inc. $IMNM - MarketBeat
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
Loss Report: Is Immunome Inc forming a breakout pattern2026 Risk Factors & Weekly Stock Breakout Alerts - baoquankhu1.vn
Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com Nigeria
Insider Buying: Jean Bienaime Acquires Additional Shares of Immu - GuruFocus
Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock - MarketBeat
Bienaime buys Immunome (IMNM) shares worth $43,670 By Investing.com - Investing.com UK
Immunome (IMNM) director buys 2,000 shares in open market - Stock Titan
Craig-Hallum Initiates Coverage of Immunome (IMNM) with Buy Recommendation - MSN
A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration - simplywall.st
Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha
Immunome (IMNM) to Release Earnings on Wednesday - MarketBeat
(IMNM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Is Immunome Inc forming a breakout patternJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Immunome (IMNM) - The Globe and Mail
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - finance.yahoo.com
Whale Trades: How do insiders feel about Immunome IncMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn
HC Wainwright Brokers Raise Earnings Estimates for Immunome - MarketBeat
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤놈 주식 (IMNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Mar 11 '26 |
Buy |
21.55 |
1,000 |
21,550 |
38,415 |
| SIEGALL CLAY B | President and CEO |
Dec 30 '25 |
Buy |
21.15 |
4,729 |
100,018 |
665,254 |
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
1.20%
0.06%
자본화:
|
볼륨(24시간):